QQQ   347.99 (-0.57%)
AAPL   177.25 (-0.03%)
MSFT   328.39 (-0.85%)
META   264.72 (+0.84%)
GOOGL   122.87 (-0.65%)
AMZN   120.58 (-0.89%)
TSLA   203.93 (+1.38%)
NVDA   378.34 (-5.68%)
NIO   7.53 (+1.62%)
BABA   79.58 (+1.16%)
AMD   118.21 (-5.64%)
T   15.73 (+0.58%)
F   12.00 (-4.69%)
MU   68.20 (-4.87%)
CGC   0.84 (-2.34%)
GE   101.53 (-0.86%)
DIS   87.96 (+0.16%)
AMC   4.51 (-2.59%)
PFE   38.02 (+2.73%)
PYPL   61.99 (-0.10%)
NFLX   395.23 (+0.57%)
QQQ   347.99 (-0.57%)
AAPL   177.25 (-0.03%)
MSFT   328.39 (-0.85%)
META   264.72 (+0.84%)
GOOGL   122.87 (-0.65%)
AMZN   120.58 (-0.89%)
TSLA   203.93 (+1.38%)
NVDA   378.34 (-5.68%)
NIO   7.53 (+1.62%)
BABA   79.58 (+1.16%)
AMD   118.21 (-5.64%)
T   15.73 (+0.58%)
F   12.00 (-4.69%)
MU   68.20 (-4.87%)
CGC   0.84 (-2.34%)
GE   101.53 (-0.86%)
DIS   87.96 (+0.16%)
AMC   4.51 (-2.59%)
PFE   38.02 (+2.73%)
PYPL   61.99 (-0.10%)
NFLX   395.23 (+0.57%)
QQQ   347.99 (-0.57%)
AAPL   177.25 (-0.03%)
MSFT   328.39 (-0.85%)
META   264.72 (+0.84%)
GOOGL   122.87 (-0.65%)
AMZN   120.58 (-0.89%)
TSLA   203.93 (+1.38%)
NVDA   378.34 (-5.68%)
NIO   7.53 (+1.62%)
BABA   79.58 (+1.16%)
AMD   118.21 (-5.64%)
T   15.73 (+0.58%)
F   12.00 (-4.69%)
MU   68.20 (-4.87%)
CGC   0.84 (-2.34%)
GE   101.53 (-0.86%)
DIS   87.96 (+0.16%)
AMC   4.51 (-2.59%)
PFE   38.02 (+2.73%)
PYPL   61.99 (-0.10%)
NFLX   395.23 (+0.57%)
QQQ   347.99 (-0.57%)
AAPL   177.25 (-0.03%)
MSFT   328.39 (-0.85%)
META   264.72 (+0.84%)
GOOGL   122.87 (-0.65%)
AMZN   120.58 (-0.89%)
TSLA   203.93 (+1.38%)
NVDA   378.34 (-5.68%)
NIO   7.53 (+1.62%)
BABA   79.58 (+1.16%)
AMD   118.21 (-5.64%)
T   15.73 (+0.58%)
F   12.00 (-4.69%)
MU   68.20 (-4.87%)
CGC   0.84 (-2.34%)
GE   101.53 (-0.86%)
DIS   87.96 (+0.16%)
AMC   4.51 (-2.59%)
PFE   38.02 (+2.73%)
PYPL   61.99 (-0.10%)
NFLX   395.23 (+0.57%)
NYSE:QGEN

Qiagen (QGEN) Competitors

$45.16
-0.13 (-0.29%)
(As of 05/31/2023 ET)
Compare
Today's Range
$44.85
$45.32
50-Day Range
$43.93
$46.76
52-Week Range
$40.38
$51.18
Volume
1.06 million shs
Average Volume
758,947 shs
Market Capitalization
$10.28 billion
P/E Ratio
29.32
Dividend Yield
N/A
Price Target
$54.87

QGEN vs. RGEN, NBIX, TECH, EXEL, CRSP, PCVX, HALO, DNLI, ABCM, and DNA

Should you be buying Qiagen stock or one of its competitors? The main competitors of Qiagen include Repligen (RGEN), Neurocrine Biosciences (NBIX), Bio-Techne (TECH), Exelixis (EXEL), CRISPR Therapeutics (CRSP), Vaxcyte (PCVX), Halozyme Therapeutics (HALO), Denali Therapeutics (DNLI), Abcam (ABCM), and Ginkgo Bioworks (DNA). These companies are all part of the "biological products, except diagnostic" industry.

Qiagen vs.

Qiagen (NYSE:QGEN) and Repligen (NASDAQ:RGEN) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, dividends, valuation, profitability, risk, community ranking, analyst recommendations, media sentiment and institutional ownership.

Repligen has a net margin of 21.58% compared to Qiagen's net margin of 17.66%. Qiagen's return on equity of 14.08% beat Repligen's return on equity.

Company Net Margins Return on Equity Return on Assets
Qiagen 17.66% 14.08% 7.61%
Repligen 21.58% 9.14% 6.87%

58.6% of Qiagen shares are owned by institutional investors. Comparatively, 91.0% of Repligen shares are owned by institutional investors. 9.0% of Qiagen shares are owned by company insiders. Comparatively, 1.1% of Repligen shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

In the previous week, Qiagen and Qiagen both had 4 articles in the media. Repligen's average media sentiment score of 0.80 beat Qiagen's score of 0.24 indicating that Repligen is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Qiagen
1 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Repligen
3 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Qiagen has higher revenue and earnings than Repligen. Qiagen is trading at a lower price-to-earnings ratio than Repligen, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Qiagen$2.14 billion4.80$423.21 million$1.5429.32
Repligen$801.54 million11.66$185.96 million$2.9556.92

Repligen received 154 more outperform votes than Qiagen when rated by MarketBeat users. Likewise, 68.07% of users gave Repligen an outperform vote while only 60.78% of users gave Qiagen an outperform vote.

CompanyUnderperformOutperform
QiagenOutperform Votes
234
60.78%
Underperform Votes
151
39.22%
RepligenOutperform Votes
388
68.07%
Underperform Votes
182
31.93%

Qiagen presently has a consensus target price of $54.87, indicating a potential upside of 21.49%. Repligen has a consensus target price of $208.56, indicating a potential upside of 24.20%. Given Repligen's stronger consensus rating and higher probable upside, analysts plainly believe Repligen is more favorable than Qiagen.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Qiagen
0 Sell rating(s)
3 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.40
Repligen
0 Sell rating(s)
2 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
2.75

Qiagen has a beta of 0.39, meaning that its share price is 61% less volatile than the S&P 500. Comparatively, Repligen has a beta of 1.08, meaning that its share price is 8% more volatile than the S&P 500.

Summary

Repligen beats Qiagen on 12 of the 17 factors compared between the two stocks.


New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding QGEN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

QGEN vs. The Competition

MetricQiagenBiological Products IndustryMedical SectorNYSE Exchange
Market Cap$10.28B$2.55B$4.50B$14.25B
Dividend YieldN/A2.33%2.32%4.06%
P/E Ratio29.323.3791.0518.25
Price / Sales4.80182.803,619.079.08
Price / Cash13.2916.1294.3423.16
Price / Book2.894.825.009.09
Net Income$423.21M$52.66M$117.46M$896.31M
7 Day Performance-0.83%-1.49%-1.67%-1.01%
1 Month Performance1.23%7.13%0.87%-2.90%
1 Year Performance-1.72%10.30%19.09%-10.41%

Qiagen Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
RGEN
Repligen
2.4755 of 5 stars
$173.34
+1.4%
$208.56
+20.3%
+1.9%$9.65B$801.54M58.762,025
NBIX
Neurocrine Biosciences
2.6424 of 5 stars
$90.11
-1.2%
$125.21
+39.0%
-3.2%$8.79B$1.49B150.191,200Positive News
TECH
Bio-Techne
2.8036 of 5 stars
$83.18
-0.4%
$104.45
+25.6%
-13.9%$13.10B$1.11B49.813,000
EXEL
Exelixis
3.0756 of 5 stars
$19.01
-0.6%
$25.33
+33.3%
+3.3%$6.19B$1.61B39.601,223Short Interest ↑
CRSP
CRISPR Therapeutics
2.1538 of 5 stars
$64.63
0.0%
$74.89
+15.9%
+10.8%$5.10B$1.20M-9.62473Analyst Report
Short Interest ↓
Analyst Revision
PCVX
Vaxcyte
1.9453 of 5 stars
$48.78
-0.4%
$65.00
+33.3%
+87.0%$4.59BN/A-14.1089Positive News
HALO
Halozyme Therapeutics
3.3754 of 5 stars
$32.85
-1.1%
$54.78
+66.8%
-32.0%$4.33B$660.12M25.08145Positive News
DNLI
Denali Therapeutics
2.1633 of 5 stars
$29.27
-2.3%
$52.09
+78.0%
+16.0%$4.01B$108.46M-10.20380Positive News
ABCM
Abcam
2.4467 of 5 stars
$16.28
-0.5%
$23.00
+41.3%
+8.7%$3.73B$447.49M0.001,760Short Interest ↓
Positive News
DNA
Ginkgo Bioworks
2.0257 of 5 stars
$1.73
+13.9%
$4.67
+170.7%
-46.3%$3.60B$477.71M-1.671,292Short Interest ↑

Related Companies and Tools

This page (NYSE:QGEN) was last updated on 5/31/2023 by MarketBeat.com Staff

My Account -